FRANCESCHINI, FRANCO
 Distribuzione geografica
Continente #
NA - Nord America 17.836
EU - Europa 11.262
AS - Asia 10.527
SA - Sud America 2.043
AF - Africa 272
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 15
AN - Antartide 1
Totale 41.982
Nazione #
US - Stati Uniti d'America 17.463
IT - Italia 4.986
SG - Singapore 3.830
CN - Cina 3.245
BR - Brasile 1.691
UA - Ucraina 1.485
HK - Hong Kong 1.234
DE - Germania 1.202
VN - Vietnam 730
FR - Francia 667
FI - Finlandia 607
GB - Regno Unito 540
RU - Federazione Russa 422
TR - Turchia 385
IE - Irlanda 375
BD - Bangladesh 265
IN - India 251
PL - Polonia 208
CA - Canada 175
NL - Olanda 151
SE - Svezia 136
AR - Argentina 127
MX - Messico 114
ZA - Sudafrica 92
ES - Italia 89
IQ - Iraq 89
JP - Giappone 81
AT - Austria 66
PK - Pakistan 62
ID - Indonesia 50
BE - Belgio 49
EC - Ecuador 48
VE - Venezuela 47
SA - Arabia Saudita 40
CO - Colombia 38
MA - Marocco 33
CZ - Repubblica Ceca 31
EG - Egitto 29
NG - Nigeria 28
UZ - Uzbekistan 28
JO - Giordania 27
LT - Lituania 27
AE - Emirati Arabi Uniti 25
EE - Estonia 25
PY - Paraguay 25
JM - Giamaica 22
AU - Australia 21
CL - Cile 21
RO - Romania 21
AZ - Azerbaigian 20
HR - Croazia 20
CH - Svizzera 19
IL - Israele 19
KE - Kenya 19
PE - Perù 18
TN - Tunisia 18
PH - Filippine 17
UY - Uruguay 17
KZ - Kazakistan 16
NP - Nepal 16
DZ - Algeria 15
PT - Portogallo 15
EU - Europa 14
SK - Slovacchia (Repubblica Slovacca) 13
AL - Albania 12
GR - Grecia 12
IR - Iran 12
CR - Costa Rica 11
HN - Honduras 11
MK - Macedonia 11
KG - Kirghizistan 10
LU - Lussemburgo 10
BG - Bulgaria 9
LB - Libano 9
PA - Panama 8
TH - Thailandia 8
TT - Trinidad e Tobago 8
BO - Bolivia 7
NI - Nicaragua 7
PS - Palestinian Territory 7
RS - Serbia 7
CI - Costa d'Avorio 6
ET - Etiopia 6
GE - Georgia 6
HU - Ungheria 6
LV - Lettonia 6
MY - Malesia 6
NO - Norvegia 6
UG - Uganda 6
AM - Armenia 5
BA - Bosnia-Erzegovina 5
BH - Bahrain 5
BY - Bielorussia 5
CY - Cipro 5
DK - Danimarca 5
KR - Corea 5
AO - Angola 4
DO - Repubblica Dominicana 4
MD - Moldavia 4
NZ - Nuova Zelanda 4
Totale 41.917
Città #
Singapore 2.005
Fairfield 1.572
Ashburn 1.563
Hong Kong 1.232
Woodbridge 1.143
Jacksonville 1.092
San Jose 1.003
Houston 837
Beijing 764
The Dalles 757
Cambridge 625
Seattle 604
Ann Arbor 587
Wilmington 577
Princeton 549
New York 511
Chandler 477
Los Angeles 445
Milan 436
Helsinki 371
Nanjing 352
Lauterbourg 311
Dublin 305
Istanbul 304
Dallas 268
Chicago 256
Rome 251
Ho Chi Minh City 247
Brescia 235
Munich 226
Warsaw 184
Buffalo 168
Hanoi 155
Moscow 152
São Paulo 145
Des Moines 130
Redondo Beach 127
Council Bluffs 123
Nanchang 122
San Francisco 120
Florence 115
San Diego 115
Shanghai 107
Hebei 105
Shenyang 105
Changsha 97
London 96
Tianjin 88
Santa Clara 87
Salt Lake City 86
Turin 77
Turku 74
Jinan 73
Tokyo 73
Nuremberg 66
Verona 65
Bologna 63
Jiaxing 63
Trieste 62
Brooklyn 59
Orem 59
Lancaster 58
Rio de Janeiro 58
Hangzhou 56
Chennai 55
Phoenix 54
Bergamo 52
Frankfurt am Main 52
Johannesburg 52
Atlanta 51
Montreal 47
Brussels 45
Genoa 44
Toronto 44
Dearborn 42
Denver 42
Mexico City 42
Guangzhou 41
Belo Horizonte 40
Amsterdam 39
Elk Grove Village 38
Tampa 38
Kunming 34
Stockholm 34
Udine 34
Dhaka 33
Naples 33
Ningbo 33
Romola 33
Vienna 33
Manchester 32
Padova 32
Lappeenranta 30
Poplar 30
Zhengzhou 30
Mumbai 29
Paris 28
Abuja 27
Baghdad 27
Haiphong 27
Totale 24.615
Nome #
ANTICORPI ANTI-TH/TO NELLA SCLEROSI SISTEMICA (SSC): CORRELAZIONI CLINICHE E IMMUNOLOGICHE 2.381
ANTICORPI ANTI-RNA POLIMERASI III: UN MARKER DI ESORDIO PRECOCE DI SCLEROSI SISTEMICA 1.830
Frequency Evaluation of the Interleukin-6 −174G>C Polymorphism and Homeostatic Iron Regulator (HFE) Mutations as Disease Modifiers in Patients Affected by Systemic Lupus Erythematosus and Rheumatoid Arthritis 704
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 478
Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression 225
Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease? 221
Anti-RNA polymerase III antibodies as a risk marker for early Gastric Antral Vascular Ectasia (GAVE) in systemic sclerosis 216
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 215
Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study 205
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 199
Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). 196
Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. 196
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 195
Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens. 194
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 189
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 184
C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis 184
Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies 181
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 180
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events. 179
Prevalence and disease-specific risk factors for Lower Urinary Tract symptoms in Systemic Sclerosis: an international multi-centric study 179
Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. 177
Systemic lupus erythematosus and endothelial dysfunction: A close relationship 177
Aortic stiffness and left ventricular hypertrophy in rheumatoid arthritis: Comment on the article by Rudominer et al. 176
Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept 174
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 173
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome 171
Antiphospholipid antibodies mediate autoimmunity against dying cells. 169
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events 169
Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events 168
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 168
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 167
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 163
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group 163
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 162
Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg? 158
Treatment and functional outcome of patients with cystoid macular edema: a single-center experience 156
The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study 156
Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins 156
The clinico-serological spectrum of overlap myositis 156
Autoimmune polyendocrine Syndromes 155
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 155
[Neonatal lupus: clinical features and risk of congenital cardiac heart block in newborns from mothers with anti Ro/SSA antibodies] 154
Antiphospholipid syndrome and glomerular thrombosis in the absence of overt lupus nephritis 153
Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis 153
Discordance for systemic lupus erythematosus and hyper IgE syndrome in a pair of monozygotic twins 150
Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors 150
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome 149
Severe skin involvement in type II cryoglobulinemia successfully treated with thalidomide 145
Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera 145
Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. 144
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. 143
Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus 142
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women 141
Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. 140
Anti-Ro/SSA and La/SSB antibodies 140
Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase 139
A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. 138
Rare autoantibodies to cellular antigens in systemic lupus erythematosus. 138
The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. 138
A prospective evaluation of endothelial dysfunction in systemic Lupus Erythematosus patients without previous cardiovascular events: preliminary results 138
A prospective evaluation of endothelial dysfunction in Systemic Lupus Erythematosus patients without previous cardiovascular events: preliminary results. 138
Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: The positive experience of a national multicentre study 136
Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis 136
Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. 134
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 134
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. 134
Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti-Tumor Necrosis Factor-α Therapy 134
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 133
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients 133
Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. 132
A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution 132
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 131
Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies 131
[TNF-alpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunologic effects] 130
Systematic Review and Meta-analysis on the Association of Occupational Exposure to Free Crystalline Silica and Rheumatoid Arthritis 130
Incidence of antiperinuclear factor in patients with psoriatic arthritis. 129
Bridging the Diagnostic Gap for Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders: Evidence of a Common Extracellular Matrix Fragmentation Pattern in Patient Plasma as a Potential Biomarker 128
Prognostic value of diastolic dysfunction in asymptomatic rheumatoid arthritis patients without cardiovascular risk factors 128
The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus 128
Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. 127
Deforming arthropathy of the hands in Systemic Lupus Erythematosus is associated with antibodies to SS-A/Ro and to SS-B/La. 127
Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. 127
Belimumab decreases flare rate and hinders the expected damage progression in patients with active systemic lupus erythematosus 127
Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. 127
Analysis of C9Orf72 Expansions in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Data 127
Clinical and morphological features of kidney involvement in primary Sjogren's syndrome. 126
ANTI-RNA POLYMERASE III ANTIBODIES AS A RISK MARKER FOR EARLY DEVELOPMENT OF GASTRIC ANTRAL VASCULAR ECTASIA IN SYSTEMIC SCLEROSIS 125
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. 125
75-SeHCAT retention test in chronic cholestatic disease: comparison with health and effect of bile acid therapy. 125
Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference 125
Myositis autoantibodies and clinical phenotypes 125
Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic 125
In vivo reflectance confocal microscopy features of cutaneous microcirculation and epidermal and dermal changes in diffuse systemic sclerosis and correlation with histological and videocapillaroscopic findings. 125
Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study 124
Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study 123
Determination of antibodies to extractable nuclear antigens by commercial kits: a multicenter study 123
Letter to editor: New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease 123
Antiperinuclear factor in psoriatic arthropathy 122
Primary biliary cirrhosis-related autoantibodies in a large cohort of italian patients with systemic sclerosis 122
Totale 19.951
Categoria #
all - tutte 199.275
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 199.275


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021622 0 0 0 0 0 0 0 0 0 0 395 227
2021/20223.010 185 401 140 176 164 200 201 234 193 296 272 548
2022/20232.266 341 38 51 99 194 564 47 229 384 56 139 124
2023/20242.853 150 84 228 246 134 458 134 138 667 94 107 413
2024/20257.324 117 156 125 734 678 592 568 343 675 585 1.492 1.259
2025/202613.532 1.224 1.862 1.068 1.878 1.336 929 2.057 583 767 1.147 681 0
Totale 42.516